



11/29/2011

**Subject: Health Canada has suspended approval of Avastin®
(bevacizumab) for use in metastatic breast cancer**

Dear Health Care Professional

This letter is to inform you that on November 25, 2011 Health Canada made a final decision to suspend the NOC/c for AVASTIN in combination with paclitaxel for treatment of patients with metastatic breast cancer (mBC).

This action is specific to AVASTIN's breast cancer indication and does not impact AVASTIN's approved uses for other cancer types in Canada.

As such, the current Product Monograph for AVASTIN, dated September 2, 2011, will be updated shortly to reflect the suspension of the metastatic breast cancer indication, including the removal of any reference to clinical trials in mBC.

The revised AVASTIN Product Monograph is not yet available, but as soon as it is revised and approved by Health Canada, it will be posted on our website:

www.rochecanada.com

Should you have any questions or require additional information regarding the use of AVASTIN, please contact the Drug Information Department at Hoffmann-La Roche Limited at 1-888-762-4388, Monday to Friday, between 8:30 a.m. and 4:30 p.m. (Eastern Standard Time).

Sincerely,

Hoffmann-La Roche Limited

original signed by

Lorenzo Biondi
Vice President,
Medical and Regulatory Affairs